Raptor Falls On Failed Investigator-Run NASH Study
This article was originally published in Scrip
Executive Summary
Raptor Pharmaceuticals fell 37.5% on Sept. 14 to $7.52 per share after the Novato, California-based company revealed that RP103, a delayed-release version of its approved cystinosis drug Procysbi (cysteamine bitartrate) failed in a Phase IIb pediatric non-alcoholic steatohepatitis (NASH) clinical trial.
You may also be interested in...
Raptor Buy Bolsters Horizon's Orphan Business As Primary Care Foots The Bill
Horizon will boost its orphan drug business through the acquisition of Raptor, using a combination of debt and cash from its primary care and other assets to fund the transaction.
Legend Biotech CEO Ying Huang On Moving Fast In the BCMA CAR-T Race
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
Finance Watch: Investors Remain Receptive To Biopharma, Health Care SPAC IPOs
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.
Need a specific report? 1000+ reports available
Buy Reports